Banking of Adipose- and Cord Tissue-Derived Stem Cells: Technical and Regulatory Issues.
Harris DT.
Narrative Review, published in Adv Exp Med Biol (2016) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Adv Exp Med Biol (2016)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 27837561
- DOI
- 10.1007/978-3-319-45457-3_12
Abstract (original English)
Stem cells are found in all multicellular organisms and are defined as cells that can differentiate into specialized mature cells as well as divide to produce more stem cells. Mesenchymal stem cells (MSC) were among the first stem cell types to be utilized for regenerative medicine. Although initially isolated from bone marrow, based on ease and costs of procurement, MSC derived from adipose tissue (AT-MSC) and umbilical cord tissue (CT-MSC) are now preferred stem cell sources for these applications. Both adipose tissues and cord tissue present unique problems for biobanking however, in that these are whole tissues, not cellular suspensions. Although the tissues could be processed to facilitate the biobanking process, by doing so additional regulatory issues arise that must be addressed. This review will discuss the technical issues associated with biobanking of these tissues, as well as regulatory concerns when banking of utilizing MSC derived from these sources in the clinic.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.